Jeffrey P. Beckenbaugh, DO






In This Edition

Peri-operative Dexamethasone for Control of Pain After Total Knee Arthroplasty

Indirect reduction and fixation of a Lateral Plateau depression fracture utilizing balloon tibioplasty in a cachectic, malnourished patient: A Case Report

Please Join Us at the Postgraduate Seminar

2012 Annual Meeting Recap

Changes Coming to the 2013 Annual Meeting

AOA Develops New Platform for Posting CME Credits for 2013-2015 Cycle

New FDA Ruling Prompts Added CME Option for Providers

Physician Payment Sunshine Act: Final Rule

Good Samaritan Regional Medical Center Orthopedic Surgery Residency Program in its Third Year

We Need More Doctors in Government - How About You?

SAOAO Report:
Student AOAO - A Glance at the Past and a Spotlight on the Future

RAOAO Report

Member Spotlight: Steven J. Heithoff, DO, FAOAO

Thank you to our preliminary exhibitors and supporters

Gold Level
DePuy Orthopaedics

Silver Level
Auxilium Pharmaceuticals
Innomed, Inc.
Smith & Nephew

Bronze Level
Biomet Orthopaedics

American Osteopathic Board of Orthopedic Surgery
Auxilium Pharmaceuticals
BioMarin Pharmaceutical Inc.
Biomet Orthopaedics
BioPro, Inc
ConforMIS, Inc.
DePuy Orthopaedics
Elsevier USA
Innomed, Inc.
Lippincott, Williams & Wilkins
Skeletal Dynamics
Smith & Nephew
The Progressive Orthopaedic Company
Wright Medical Technology, Inc.

Commercial Support
AOAO would like to thank the following companies for providing an educational grant:

DePuy Synthes USA

For the up-to-date list of exhibitors and products descriptions, click here.

New FDA Ruling Prompts Added CME Option for Providers

The FDA has developed a risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioid products in response to extensive data and statistics which have shown an increase in death rates due to opioid use. They have launched a campaign to develop a strategy to manage known or potential serious risks associated with a drug product to ensure that the benefits of a drug outweigh its risks. For additional information on this campaign and the products covered, visit http://www.er-la-opioidrems.com/IwgUI/rems/home.action.

Part of this strategic campaign is to require ER/LA opioid analgesics manufacturers, known as the REMS Program Companies (RPC), to provide education for prescribers of these medications. RPC-supported REMS education will be provided through accredited continuing education (CE) activities supported by independent educational grants from these ER/LA opioid analgesic companies.
The American Osteopathic Association has joined the list of accrediting bodies to provide REMS education to physicians. The AOA is offering block grants to subspecialties that wish to provide REMS education to physicians between May 1, 2013 and April 30, 2014.

The American Osteopathic Academy of Orthopedics is working with the AOA to obtain a block grant to help fund REMS education for our members during the 2013 Annual Meeting. Watch for additional information regarding the date and time. Those who participate in REMS education will received AOA Category 1-A CME Credit.

Information regarding the FDA’s ruling and REMS education is available through the AOA’s website at http://www.osteopathic.org/inside-aoa/development/continuing-medical-education/Pages/rems.aspx.

ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care

AOAO Annual Meeting, San DiegoThursday, October 17, 2013, 8:00 to 11:00 a.m.

“ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care” will be presented at the AOAO Annual Meeting in San Diego, CA, on Thursday, October 17, 2013, from 8:00 to 11:00 a.m., immediately following the opening keynote address. The three-hour session provides three hours of AOA Category 1-A CME credit.

The “ER/LA Opioid REMS” program has been developed by the Collaborative for REMS Education (CO*RE). The American Osteopathic Association (AOA) is a CO*RE partner. CO*RE recently received approval from the REMS Program Committee (RPC) for its national initiative to support educational activities addressing the public health crisis surrounding the use, abuse, diversion and overdose associated with Extended Release/Long Acting (ER/LA) opioids. As a result of that action, the AOA invited affiliates to apply for block grants to present the REMS program. The American Osteopathic Academy of Orthopedics (AOAO) has received an AOA block grant to present the “ER/LA Opioid REMS” program.

A Risk Evaluation and Mitigation Strategy (REMS) is a risk management program required by the U.S. Food and Drug Administration (FDA) to ensure that the benefits of a drug outweigh its risks. The FDA has determined that a single, shared REMS is required for all brand and generic ER/LA opioid pain medicines.  This is the first time the FDA has mandated a REMS to include accredited professional education. The FDA has also required the pharmaceutical companies that produce these agents to provide the financial support for independent professional education. The “ER/LA Opioid REMS” program uses a standardized education module based on the approved FDA Blueprint. The program will be presented by a DO who has participated in the CO*RE master faculty training.

At the conclusion of this program, participants should be able to:

  1. Describe appropriate patient assessment for treatment with ER/LA opioid analgesics, evaluating risks and potential benefits of ER/LA therapy as well as possible misuse.
  2. Apply proper methods to initiate therapy, modify dose, and discontinue use of ER/LA opioid analgesics, applying best practices including accurate dosing and conversion techniques as well as appropriate discontinuation strategies.
  3. Demonstrate accurate knowledge about how to manage ongoing therapy with ER/LA opioid analgesics and properly use evidence-based tools while assessing for adverse effects.
  4. Employ methods to counsel patients and caregivers about the safe use of ER/LA opioid analgesics, including proper storage and disposal.
  5. Review/assess general and product-specific drug information concerning ER/LA opioid analgesics and identifying potential adverse effects of ER/LA opioids.

This program is presented by the American Osteopathic Association, a member of the Collaborative on REMS Education (CO*RE), ten interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.

RPC Commercial Support Disclosure Statement:
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies (RPC). Please see www.er-la-opioidREMS.com for a listing of the member companies.

This activity is intended to be fully-compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the U.S. Food & Drug Administration (FDA).

Back to top